1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism
- PMID: 15855208
- DOI: 10.1093/ndt/gfh834
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism
Abstract
Background: Calcitriol treatment of secondary hyperparathyroidism (HPT) in chronic kidney disease (CKD) patients can lead to increased serum calcium and phosphorus, which have been associated as risk factors for vascular calcification. Cinacalcet HCl (Sensipar/Mimpara) {(alphaR)-(-)-alpha-methyl-N-[3-[3-(trifluoromethylphenyl)propyl]-1-napthalenemethanamine hydrochloride} lowers serum parathyroid hormone (PTH), calcium, phosphorus and calcium-phosphorous (CaxP) product in stage 5 CKD dialysis patients; however, its effects on vascular calcification are unknown.
Methods: Cinacalcet HCl (10 or 1 mg/kg, p.o. gavage), 1,25-dihydroxyvitamin D(3) (0.1 microg, s.c, calcitriol) or the combination was administered daily for 26 days in a rat model of secondary HPT [5/6 nephrectomy]. After dosing, aortic calcification was determined using the von Kossa staining method. Serum PTH and blood chemistries were determined on days 0, 26 and 0, 14, 26, respectively, prior to and after dosing.
Results: Calcitriol-treated rats had moderate to marked aortic calcification, whereas no significant calcification was observed in vehicle- or cinacalcet HCl-only treated groups. Co-administration of cinacalcet HCl with calcitriol did not attenuate the calcitriol-mediated increase in CaxP product or calcitriol-mediated aortic calcification. Both calcitriol and cinacalcet HCl therapy significantly reduced serum PTH levels. Calcitriol significantly elevated serum calcium, serum phosphorous and CaxP product above pretreatment levels, or those seen with vehicle or cinacalcet HCl. Cinacalcet HCl (10 or 1 mg/kg) decreased serum ionized calcium and decreased calcitriol-induced hypercalcaemia.
Conclusion: Cinacalcet HCl and calcitriol both effectively reduce PTH, albeit via different mechanisms, but unlike calcitriol, cinacalcet HCl did not produce hypercalcaemia, an increased CaxP product or vascular calcification.
Comment in
-
Cinacalcet and vascular calcifications induced by calcitriol.Nephrol Dial Transplant. 2006 Feb;21(2):551-2. doi: 10.1093/ndt/gfi200. Epub 2005 Oct 12. Nephrol Dial Transplant. 2006. PMID: 16221695 No abstract available.
Similar articles
-
Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.Kidney Int. 2005 Feb;67(2):467-76. doi: 10.1111/j.1523-1755.2005.67103.x. Kidney Int. 2005. PMID: 15673294
-
Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.Expert Opin Pharmacother. 2005 Mar;6(3):441-52. doi: 10.1517/14656566.6.3.441. Expert Opin Pharmacother. 2005. PMID: 15794735 Review.
-
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.Am J Kidney Dis. 2009 Feb;53(2):197-207. doi: 10.1053/j.ajkd.2008.09.021. Epub 2008 Dec 24. Am J Kidney Dis. 2009. PMID: 19110359 Clinical Trial.
-
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.Nephrol Dial Transplant. 2005 Oct;20(10):2186-93. doi: 10.1093/ndt/gfh966. Epub 2005 Jul 19. Nephrol Dial Transplant. 2005. PMID: 16030053 Clinical Trial.
-
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.J Ren Nutr. 2006 Jul;16(3):253-8. doi: 10.1053/j.jrn.2006.04.010. J Ren Nutr. 2006. PMID: 16825031 Review.
Cited by
-
The calcium-sensing receptor and calcimimetics in blood pressure modulation.Br J Pharmacol. 2011 Oct;164(3):884-93. doi: 10.1111/j.1476-5381.2011.01317.x. Br J Pharmacol. 2011. PMID: 21410453 Free PMC article. Review.
-
Calcimimetics and Vascular Calcification.Toxins (Basel). 2025 Jun 12;17(6):297. doi: 10.3390/toxins17060297. Toxins (Basel). 2025. PMID: 40559875 Free PMC article. Review.
-
Cinacalcet ameliorates aortic calcification in uremic rats via suppression of endothelial-to-mesenchymal transition.Acta Pharmacol Sin. 2016 Nov;37(11):1423-1431. doi: 10.1038/aps.2016.83. Epub 2016 Sep 5. Acta Pharmacol Sin. 2016. PMID: 27593220 Free PMC article.
-
Research Models for Studying Vascular Calcification.Int J Mol Sci. 2020 Mar 23;21(6):2204. doi: 10.3390/ijms21062204. Int J Mol Sci. 2020. PMID: 32210002 Free PMC article. Review.
-
Comparison of AMG 416 and cinacalcet in rodent models of uremia.BMC Nephrol. 2014 May 19;15:81. doi: 10.1186/1471-2369-15-81. BMC Nephrol. 2014. PMID: 24884838 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources